key: cord-0277924-ptw17s4i
authors: Unali, G.; Giordano, A.M.S; Cuccovillo, I.; Alezz M., Abou; Apolonia, L.; Merelli, I.; Malim, M. H.; Petrillo, C.; Kajaste-Rudnitski, A.
title: The lysine-rich intracellular loop and cell type-specific co-factors are required for IFITM3 antiviral immunity in hematopoietic stem cells
date: 2021-04-06
journal: bioRxiv
DOI: 10.1101/2021.04.06.438585
sha: 6e812dcb7190fe577c3eb0cdec51c09573d06240
doc_id: 277924
cord_uid: ptw17s4i

The interferon-induced transmembrane protein 3 (IFITM3) inhibits lentiviral gene therapy vector entry into hematopoietic stem cells and can be overcome by Cyclosporine H (CsH), but underlying mechanisms remain unclear. Here, we show that mutating the evolutionarily conserved lysines of the IFITM3 intracellular loop abolishes its antiviral activity without affecting either its localization or its degradation by CsH through non-canonical lysosomal pathways. When confined to the plasma membrane, the lysine-competent IFITM3 lost restriction against VSV-G pseudotyped viral vectors but gained antiviral activity against vectors that fuse directly at the plasma membrane. Interestingly, altering the lysines did not alter IFITM3 homodimerization but impacted higher-order protein complex formation, suggesting loss of interaction with cellular co-factors. In agreement, IFITM3 expression was not sufficient to restrict viral vectors in myeloid K562 cells as opposed to promonocytic THP1 or primary HSC. We exclude the involvement of previously identified factors affecting IFITM3 biology and propose a novel model for IFITM3 restriction that depends on the presence of cellular co-factor(s) that may interact with IFITM3 through the intracellular loop lysine residues. Overall, our work provides significant insight into the mechanisms of action of IFITM3 and CsH that can be exploited for improved gene therapies and broadly acting antiviral strategies.

5 93 described to suppress HIV-1 protein synthesis by impeding viral mRNA transcription 94 in the polysomes (28).

Here, we have investigated the molecular determinants of IFITM3-mediated 96 inhibition of viral gene therapy vectors in human hematopoietic cell lines as well as in 97 primary HSPC and addressed how CsH induces its degradation. Our work uncovers 98 the requirement of co-factors and a critical region for IFITM3 antiviral activity and 99 provides insight into the proteolytic pathways involved in CsH-mediated counteraction 100 of this antiviral protein.

6 102 Results

104 CsH degrades IFITM3 through lysosomal pathways 105 We have previously shown that CsH increases LV transduction through transient 106 degradation of IFITM3 in HSPC but the mechanisms remain unclear (6). As 107 Cyclosporins are known to bind cyclophilins (Cyp) (Quesniaux et al, 1987), we firstly 108 assessed whether knock-out of the known targets Cyp A, D or F could affect IFITM3

109 restriction or CsH-mediated inhibition of IFITM3 in THP1 (Fig. 1A-B) . However, knock-110 out of Cyclophilins did not affect LV transduction sensitivity to IFNα or CsH ( Fig. 1A- 111 B). These data suggest that IFITM3 and CsH-mediated effects in THP1 are 112 independent from Cyclophilins.

IFITM3 has been reported to impede viral egress from the endo-lysosomal 114 compartments (12). In agreement, we observed that LV pseudotyped with mutant 115 VSV-G glycoproteins that are less efficient in fusing with the endo-lysosomal 116 membranes were severely impaired in THP1 over-expressing IFITM3 and HSPC ( Fig.   117 1C-D) . Moreover, these vectors were the ones to benefit the most from CsH that 118 restored their transduction to the levels of those of a LV pseudotyped with wild-type 119 VSV-G envelope. However, altering lipid membrane stability through Amphotericin B 120 did not rescue IFITM3 restriction (Fig.1E ) as opposed to previous observations for IAV 121 in the lung epithelial A549 cell line (29, 30), suggesting distinct mechanisms of action 122 in this context. In addition, IFITM3 did not inhibit vectors pseudotyped with 123 glycoproteins fusing directly at the plasma membrane such as BaEV-TR, RD114 or 124 Measles envelopes that remained also insensitive to CsH-mediated enhancement of 125 transduction (Fig. 1E-F-G) . Of note, we also confirmed that the non-enveloped vector 7 126 AAV6 remains insensitive to IFITM3 restriction and CsH in HSPC despite entering 127 through endocytosis ( Fig. 1H -I) (6).

In order to dissect where CsH-mediated degradation of IFITM3 takes place in the 129 cell, we blocked the two best-characterized pathways involved in protein degradation, 130 namely the proteasomal and lysosomal degradation (31). Neither increased 131 transduction nor IFITM3 degradation were affected by addition of the proteasome 132 inhibitor MG132 in THP1 or HSPC ( Fig. 2A-C; 2H) . Moreover, in agreement with 133 previous reports (32), proteasomal inhibition enhanced LV transduction in HSPC and 134 the effect was additive to that of CsH (Fig. 2B) , likely indicating that MG132 may act 135 on a different restriction block that we predict is independent from IFITM3. In contrast, 136 inhibition of lysosomal degradation by Bafilomycin was sufficient to block both CsH 137 enhancement of transduction as well as IFITM3 degradation ( Fig. 2D-F ; 2H-I).

138 Consistent with a block of IFITM3 turnover in the endo-lysosomes we observed a 139 significant increase in IFITM3 protein expression in THP1 and HSPC treated with 140 Bafilomycin (Fig. 2G-I) . This effect, in combination with the capacity of Bafilomycin to 141 inhibit acidification of endo-lysosomes, may explain the strong inhibition of LV 142 transduction observed after Bafilomycin exposure ( Fig. 2D-E) . Because Bafilomycin 143 inhibits also early and late autophagy we tested whether autophagy inhibition through 144 different compounds may lead to the same observations. However, neither 3MA nor 145 Spautin-1 treatment altered CsH-mediated rescue of transduction in THP1 or HSPC 146 ( Fig. S1 A-D) , indicating that lysosomal-specific degradation pathways are involved in 147 the CsH-mediated degradation of IFITM3.

Noteworthy, we observed that the plasma-membrane confined IFITM3 Y20

149 phosphomutants that we have previously shown to have lost antiviral activity against 150 VSV-G LV in HSPC (6) inhibited plasma-membrane (PM) fusing vectors such as 8 151 BaEV, RD114 and Measles pseudotyped LV (Fig. 3A) . However, the Y20 mutant was 152 resistant to CsH degradation (Fig. 3B) , which we suggest explains why CsH could not 153 rescue its antiviral activity against PM-fusing LV in THP1 (Fig. 3A) . The Y20 mutant 154 insensitivity to CsH could be ascribed to its altered cellular localization (Fig. 3B) (Fig. 4C) .

Ubiquitination of the lysine residues is central for protein degradation (37). In 

As the infected cells can up-regulate the histone demethylase LSD1 to remove 193 Set7 methylation and promote IFITM3 antiviral activity (40) we also tested a LSD1-194 specific inhibitor and noted that it did not affect IFITM3 antiviral activity in THP1 cells 195 over-expressing IFITM3 or primary HSPC ( Fig. S3 A-B) . In agreement with specific 196 inhibition, LSD1 protein down-regulation by LSD1 inhibitor lead to increased 197 methylation of the histone H3K9 but did not affect IFITM3 protein expression ( Fig. S3 198 C). Taken together, these data invoke a mechanism of degradation of IFITM3 by CsH 199 that does not depend on any single lysine of IFITM3 nor Set7-mediated methylation. 229 likely excluding a lack of dimerization as the mechanism behind loss of antiviral activity 230 of the lysine-less IFITM3 (Fig.7B ). However, we observed a difference in higher order 231 protein complex formation with increased ratio of IFITM3 dimers over higher molecular 232 weight complexes (Fig. 7B) , suggesting potential loss of co-factor interactions 233 necessary for IFITM3 antiviral activity. In agreement, over-expression of IFITM3 was

234 not sufficient to restrict LV transduction in the myeloid cell line K562 (Fig.7C ). Of note, 235 also IFNα failed to inhibit transduction in these cells despite readily inducing 236 expression of IFN-stimulated genes, including endogenous IFITM3 (Fig. 7D) . Defects 237 in IFITM3 localization were excluded by IF analysis (Fig. 7E) . Restoring the lysine in 238 position 24 did not re-establish IFITM3 restriction in THP1 cells (Fig. 7F) indicating 

In agreement with a block at the level of the VSV-G hemi-fusion with the endo-267 lysosomes, IFITM3 Y20 phosphomutants that were retained at the plasma-membrane 268 showed loss of antiviral activity against VSV-G LV. Conversely, these mutants gained 269 antiviral activity against LV entering through direct fusion at the cell surface. 

The lysine residues in the CD225 region of IFITM3 and cell-type specific co-factors

To determine whether CsH-mediated degradation of IFITM3 could occur lacking all the lysine residues (Fig. 6A). Arginines were selected for lysine 206 substitution in order to maintain the basic charges and preserve conformation

Trafficking alterations of the mutant were excluded by 210 localization studies performed in THP1 or in primary human monocyte-derived 211 macrophages (MDM) (Fig. 6C-D) in which CsH-mediated enhancement of 212 transduction can be recapitulated upon type I IFN stimulation (Fig. 6E). Remarkably, 213 CsH was still capable of degrading this lysine-less mutant

NMR studies suggest that lysine-less IFITM3 has no topological changes, as 217 the lysines are in an intra-cytosolic portion that does not span the lipid membrane

Studying the positioning of the mutated lysines 220 we noticed that Lys83, Lys88 and Lys104 clustered together in the intracellular loop 221 (CIL), known to be part of the most evolutionarily conserved CD225 domain of IFITM3 222 (19) (Fig. 6A). Similarly, we observed that the three lysines are conserved among the 223 antiviral IFITMs and maintained across species

All cytometric analyses were performed using the FACSCanto III instrument and

Cytoflex S instruments (BD Biosciences) and analysed with the FACS Express 426 software

438 Biotechnology catalogue number sc-134310); mouse monoclonal antibody (Ab) raised 439 against CypD/F (1:1000 dilution, Abcam catalogue number [E11AE12BD4] 440 ab110324), rabbit anti-IFITM3 polyclonal Ab (1:1000 dilution, from proteintech 441 catalogue number 11714-1-AP); mouse anti-Fyn monoclonal Ab (1:3000 dilution

Abcam catalogue number ab8898)

:10000 Sigma-Aldrich catalogue number)was

For native protein extraction, 3x10 5 cells were pelleted for each condition

Protein lysates 451 were left rotating on-wheel at 4 °C for 15 min and cleared by 15 min of centrifugation 452 at 4°C at 13200 (max speed). Protein supernatants were transferred in new empty 453 tube and quantified as previously described

For Native PAGE, 7% Running native gel and 4% Stacking buffer 3X

3% DOC and Bromophenol blue) were run at 4°C for 4 hours at 15 mA

Samples were transferred to a Nitrocellulose membrane by electroblotting and blotted 462 with rabbit anti-IFITM3 polyclonal Ab (1:1000 dilution, from proteintech catalogue 463 number 11714-1-AP), anti-Vinculin

Sigma-Aldrich) for 20 at room temperature. For blocking non-specific sites cells were incubated 471 30 minutes in PBG (5% BSA, 2% gelatin from cold water fish skin, from Sigma-Aldrich) 472 and then stained for 2 till 16 hours with rabbit anti-IFITM3 polyclonal antibody (1:200 473 dilution from proteintech catalogue number 11714-1-AP) and mouse anti-LAMP1 Unali et al., Draft IFITM3 lysines and co-factors are required for LV restriction in HSPC 21 474 monoclonal antibody (1:100 dilution from Abcam [H4A3] (ab25630))

Antiviral immunity and nucleic acid sensing in 531 haematopoietic stem cell gene engineering

Cellular innate immunity and restriction of viral 533 infection: implications for lentiviral gene therapy in human hematopoietic cells

Inflammatory modulation of HSCs: viewing the HSC as 539 a foundation for the immune response

Intrinsic 541 Immunity Shapes Viral Resistance of Stem Cells

Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral 544 Transduction and Gene Editing In Human Hematopoietic Stem Cells

IFITM-Family Proteins: The Cell's 24

IFITM Genes, Variants, and Their 549 Roles in the Control and Pathogenesis of Viral Infections

552 restricts influenza A virus entry by blocking the formation of fusion pores following 553 virus-endosome hemifusion

The 558 IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, 559 and dengue virus

IFITMs restrict the replication of 561 multiple pathogenic viruses

Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and 564 influenza A virus

The IFITM proteins inhibit HIV-1

Opposing 568 activities of IFITM proteins in SARS-CoV-2 infection

Combined approaches of 570 EPR and NMR illustrate only one transmembrane helix in the human IFITM3

Interferon-induced 573 transmembrane protein 3 is a type II transmembrane protein

Regulation of the trafficking and 576 antiviral activity of IFITM3 by post-translational modifications

The 579 CD225 domain of IFITM3 is required for both IFITM protein association and inhibition 580 of influenza A virus and dengue virus replication

582 directly engages and shuttles incoming virus particles to lysosomes

Phosphorylation of the endocytosis and ubiquitination

Interference with the production of infectious viral particles and bimodal inhibition of 591 replication are broadly conserved antiviral properties of IFITMs

The 594 antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral 595 entry

IFITM 597 proteins restrict viral membrane hemifusion

Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein

Amphotericin 607 B increases influenza A virus infection by preventing IFITM3-mediated restriction

Interferon-induced transmembrane protein 3 blocks fusion of sensitive but not resistant 611 viruses by partitioning into virus-carrying endosomes

The cell : a molecular approach

Proteasome 616 activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-617 regulated by cytokines that enhance transduction

The N-terminal region of 619 IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization

Draft IFITM3 lysines and co-factors are required for LV restriction in HSPC 27 621 34

Promotes Influenza Virus Infection by Decreasing Levels of the Antiviral Protein 623 IFITM3

Natural 625 mutations in IFITM3 modulate post-translational regulation and toggle antiviral 626 specificity

S-palmitoylation and ubiquitination 628 differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated 629 resistance to influenza virus

Lysine-targeting specificity in ubiquitin and ubiquitin-like 631 modification pathways

IFITM3 requires an amphipathic helix for antiviral activity

Negative regulation of 636 interferon-induced transmembrane protein 3 by SET7-mediated lysine 637 monomethylation

Histone demethylase 639 LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation

Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on 643 Entry of Human Coronaviruses

Draft IFITM3 lysines and co-factors are required for LV restriction in HSPC 28

Homology-guided identification of a conserved motif linking the antiviral functions of 646 IFITM3 to its oligomeric state

Interferon-inducible 648 transmembrane protein 3 (IFITM3) restricts reovirus cell entry

The balance of protein expression and degradation: an

ESCRTs point of view

Targeting proteins for degradation

Immunoproteasome activation enables human TRIM5alpha restriction of HIV-1. Nat

Intrinsic cellular defenses against 658 human immunodeficiency viruses

HIV Restriction Factors and Mechanisms of Evasion

Cyclophilin A protects HIV-1 from restriction by human TRIM5alpha

Formyl peptide receptors 665 at the interface of inflammation, angiogenesis and tumor growth

Draft IFITM3 lysines and co-factors are required for LV restriction in HSPC 29

mTOR inhibitors lower an intrinsic 668 barrier to virus infection mediated by IFITM3

Major Actors 674 in Membrane Trafficking and Lipid Signaling Pathways

Phosphoinositides in the control of lysosome 676 function and homeostasis

Phosphatidylinositol 3-phosphates-at the interface 678 between cell signalling and membrane traffic

Cellular functions and molecular 680 mechanisms of non-lysine ubiquitination

Tying up loose ends: the N-degron and C-degron pathways 682 of protein degradation

N-degron and C-degron pathways of protein degradation

Generation of HIV-1 derived lentiviral vectors

Characterization of pH-30

virus glycoprotein from the postfusion state toward the prefusion state

Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into 699 early-cytokine-stimulated and resting HSCs

Efficient transduction of myeloid cells by 701 an HIV-1-derived lentiviral vector that packages the Vpx accessory protein

Comparative Study 704 of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV

A double-switch vector 707 system positively regulates transgene expression by endogenous microRNA 708 expression (miR-ON vector)

TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity

-responsive long terminal repeat elements

The 2',5'-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus 715 replication inside infected cells

Reference sequence (RefSeq) database at NCBI: current status, taxonomic 718 expansion, and functional annotation

Fast, scalable 720 generation of high-quality protein multiple sequence alignments using Clustal Omega

InterPro: the integrative protein signature database

Jalview Version 726 2--a multiple sequence alignment editor and analysis workbench

Protein sequence alignments: a strategy for the 729 hierarchical analysis of residue conservation

THP1 735 were transduced with a KO-LV expressing both Crispr-Cas9 protein and RNA guide 736 against Cyclophilin A (A), Cyclophilin D or F (B) and then re-challenged with a vector 737 after 24h of stimulation with IFNα. Values are presented as mean ± SEM (n=5-3), p 738 values are for Mann Whitney test. * for p<0.05, **for p<0.01. Cyclophilins knock-out 739 was verified by WB at the time of transduction (TD) (n=3). C. VSV-G wild-type (WT) 740 and mutant LV titers were measured by FACS analysis in THP1 over-expressing Unali

Data are presented as mean ± SEM (n=3). D. CB-HSPC were 742 transduced with VSV-G wild-type or mutant LV in presence or absence of CsH

Transduction efficiencies were measured by FACS five days after TD. Data are 744 presented as mean ± SEM (n=3). E-F. THP1 over-expressing IFITM3 or controls (E) 745 and HSPC were transduced with VSV-G LV in presence or absence of CsH

Amphotericin B or the combination of the two compounds. TD levels were evaluated 747 at FACS 5 days post TD. Data are shown as mean ± SEM (n=5-2)

* for p<0.05, **for p<0.01. G-M. THP1 over-expressing (Oe) 749 IFITM3 and controls were transduced with BaEV-TR (n=9) (G), Measles

RD114 (n=6) (I) envelope-pseudotyped LV at MOI 1 and AAV6 (n=5) (L) at MOI 10000

Transduction levels were assessed by FACS five days after TD for LV and three days 752 after TD for AAV6. M. AAV6 transduction was evaluated in CB-HSPC treated or not 753 with CsH three days post-TD (n=4)

A-D) and human CB-HSPC (B-E) were transduced 757 with VSV-G LV in presence or absence of CsH, the proteasomal inhibitor MG132, the 758 lysosomal inhibitor Bafilomycin or the combination of CsH with one of the two 759 inhibitors. Transduction efficiency was evaluated at FACS five days post-TD

IFITM3 protein expression was 762 measured by WB after an O/N treatment with CsH, MG132, Bafilomycin or the 763 combination of CsH with one of the two inhibitors in THP1 pre-stimulated with IFNα, 764 one representative image is shown. IFITM3 was quantified and normalized to Actin 765 using ImageJ (n=3-5). G. IFITM3 protein was quantified in THP1 treated or not with Unali et al., Draft IFITM3 lysines and co-factors are required for LV

Bafilomycin using ImageJ, normalization was performed over Actin. Data are shown 767 as mean ± SEM (n=6), p values are for Wilcoxon test, * for p<0

Bafilomycin to CsH. A. THP1 over-expressing IFITM3 wild-type, IFITM3-Y20 778 mutants and controls were transduced with BaEV-TR LV, RD114 LV and Measles LV 779 at MOI 0,5-1 with or without CsH. Transduction efficiency was measured by FACS five 780 days after transduction

Mann Whitney test, * for p<0.05, **for p<0.01, ***for p<0.001, ****for p<0

01, ****for p<0.0001. IFITM3 degradation was assessed also by WB (n=4)

Transduction was 790 measured by FACS five days later. Data are shown as mean ± SEM (n=4), p values Unali et al., Draft IFITM3 lysines and co-factors are required for LV restriction in HSPC 34 791 are for Mann Whitney test, **for p<0.01. D-E. THP1 over-expressing IFITM3 and 792 controls (D) and HSPC (E) were transduced with VSV-G LV in presence or absence 793 of CsH or the Src-kinase inhibitor PP2

THP1 over-expressing (Oe) IFITM3 wild-type, IFITM3 defective for the 798 interaction domain with the ubiquitin ligase NEDD4 (∆Prol) or control were transduced 799 at MOI 1 with VSV-G LV. Transduction efficiency was evaluated by FACS five days 800 post-TD. Data represent the mean ± SEM (n=7)

IFITM3 protein expression was measured by WB at time of transduction 802 (n=4). B. IFITM3 wild-type and IFITM3 ∆Prol degradation by CsH was assessed by IF 803 and WB in THP1 after 16h of CsH treatment

Data represent the mean ± SEM of four independent experiments (n=12 images), p 805 values are for Mann Whitney test. ****for p<0.0001. C. Co-localization

Draft IFITM3 lysines and co-factors are required for LV restriction in HSPC 35 816 protein levels were assessed by WB at time of transduction. B. IFITM3 wild-type and 817 single lysine mutants co-localization with LAMP-1 was evaluated by IF

Immunofluorescence images were acquired using TCS SP5 Leica confocal 819 microscope, 60x with oil. Zoomed images are shown (n=12five experiments (n=12), p values are for Mann Whitney test. * for p<0.05, **for in red. B. THP1 over-expressing

wild-type, IFITM3 lysine-less mutant or control were transduced at MOI 1 with VSV-G

Transduction 831 level was measured by FACS. Error bars represents the mean ± SEM (n=8), p value 832 are for Mann Whitney test. ****for p<0.0001. C-D. Immunofluorescence images were 833 performed using TCS SP5 Leica confocal microscope

MDM (D) to assess co-localization (purple area marked by white arrows) of IFITM3 835 and IFITM3 lysin-less mutant (in red) with the lysosomal marker LAMP1

Zoomed images are shown for THP1. E. Human monocyte-derived macrophages 837 (MDM) were pre-stimulated with IFNα for 24h and then transduced with LV at MOI 1

Transduction efficiency was measured by FACS five days after TD. Data are shown 839 as mean ± SEM (n=7) F-G. IFITM3 or IFITM3 lysine-less degradation by CsH was 840 investigated by IF in THP1 and MDM after 16h treatment with CsH. CsH-mediated Unali et al., Draft IFITM3 lysines and co-factors are required for LV

The lysines of the intracellular loop of IFITM3 and cell-type specific co-847 factors are required for antiviral activity. A. Partial protein alignment of the lysine-848 rich CIL domain of human antiviral IFITMs and IFITM3 across different species

Transduction efficiency was measured by FACS in THP1 over-expressing (Oe)

IFITM3 triple lysine mutant or control transduced at MOI 1 with VSV-G LV

862 Degradation of IFITM3 wild-type and triple lysine mutant IFITM3 was measured after 863 16h treatment with CsH in THP1 and MDM by IF. Data represent the mean ± SEM of 864 at least three independent experiments (n=12 images), p values are for Mann Whitney 865 test

CsH degrades IFITM3 independently from autophagy. A-C. THP1 over-868 expressing (Oe) IFITM3 or controls (A-C) and CB-HSPC (B) were transduced after an

Data represent the mean ± SEM (n=3-5), p values 872 are for Mann Whitney test. * for p<0.05. B-D. IFITM3 degradation by CsH was 873 investigated by WB in THP1 after 16h treatment with CsH alone or in combination with 874 one of the autophagy inhibitors. Representative images are shown

Figure S2. IFITM3 single-lysine mutants localize in the endo-lysosomes

Data represent the mean ± SEM of five experiments (n=12)

CsH-mediated degradation of IFITM3 is independent from Lys88 882 methylation. A-B. THP1 over-expressing IFITM3 or control (A) and CB-HSPC (B)

Lysine-less IFITM3 mutant maintains CsH sensitivity. IFITM3 or 890 IFITM3 lysine-less degradation by CsH was investigated by IF using TCS SP5 Leica Unali et al., Draft IFITM3 lysines and co-factors are required for LV restriction in HSPC 38

The lysines in the intracellular loop of IFITM3 are not required for 894 endolysosomal localization and CsH-mediated degradation. A. IFITM3 wild-type 895 or IFITM3 triple lysine mutant (in red) co-localization (purple areas marked by white MDM by IF using TCS SP5 Leica confocal microscope 60x with oil

Representative images are shown (n>8)